Neratinib before surgery for HER2-mutated invasive lobular breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older, and you must have recently consented to join the study
- Have a new diagnosis of stage I–III invasive lobular breast cancer that is hormone-receptor positive (ER positive)
- Have a confirmed HER2-activating mutation in tumor tissue (from a prior lab test or by doing a central lab test on available tissue)
- Have no prior treatment for this breast cancer diagnosis (no prior endocrine therapy within the last 2 years)
- Be healthy enough for treatment tests: good blood counts, liver/kidney function, and strong ability to do usual activities (ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs—neratinib alone or with palbociclib—for people with HER2-positive solid tumors (other than breast cancer) that have returned or not gone away. The goal is to see if blocking HER2 and CDK4/6 can shrink or slow the tumor.
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
This trial tests whether taking neratinib for one extra year can reduce the risk of breast cancer returning in women who had a complete response (no cancer found) after initial treatment but still have high-risk features. It is for women with HER2-positive early breast cancer.
This trial tests whether taking hormone therapy before surgery can improve outcomes for women with a specific type of breast cancer called lobular breast cancer. If you qualify, you would receive endocrine therapy for 6 months before your planned breast-conserving surgery.
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
This trial tests whether adding a second drug (neratinib) to standard hormone therapy can help women with a specific type of advanced breast cancer that has stopped responding to initial treatment. The goal is to see if the combination slows cancer growth better than hormone therapy alone.
Hear when a new Anatomic Stage I Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.